Every material Form 8-K Envista has filed with the SEC since May 30, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Envista reported third-quarter 2026 sales of $691.5 million, up 3.2% from a year earlier, with core sales growth of 2.7%. GAAP diluted EPS was $3.11, compared with a loss of $0.18 a year earlier, but that result includes a non-cash $428 million foreign currency translation gain, while adjusted diluted EPS rose to $0.40 from $0.32. The company raised its full-year 2026 adjusted diluted EPS guidance to $1.54 to $1.58 from $1.50 to $1.55.
Q3 sales $691.5 million vs. $669.9 million a year earlier; core sales growth 2.7%
GAAP diluted EPS $3.11 includes a $428 million non-cash currency translation gain ($2.62 per diluted share before tax)
Adjusted EBITDA $105.8 million, up from $97.1 million; adjusted EBITDA margin 15.3%
Updated 2026 guidance: adjusted diluted EPS $1.54 to $1.58 (prior $1.50 to $1.55); adjusted EBITDA growth 12.5% to 14% (prior 11% to 14%)
Envista Holdings announced the publication of its 2025 Sustainability Report, its sixth annual report, covering progress on dental care access, employees, communities, environmental efficiency and governance. The filing is a furnished press release with no financial results, guidance or transaction, so it does not change the company's financial outlook.
Waste generation fell 40% year over year in 2025.
Water consumption fell 19% year over year in 2025.
The Envista Smile Project donated $2.4 million and benefited close to 20,000 patients, and the lost time injury rate fell 17% year over year.
Envista's board named President and CEO Paul Keel as Chair of the Board, effective August 19, 2026, succeeding Scott Huennekens, who becomes Lead Independent Director. The Compensation Committee also approved a $200,000 base salary increase for Keel and a one-time equity award valued at $10 million, plus a $1.5 million PSU award for CFO Eric Hammes, tied to four-year relative total stockholder return.
Paul Keel, President and CEO since joining in May 2024, becomes Chair of the Board effective August 19, 2026
Keel's base salary rises $200,000, from $1.1 million to $1.3 million per year, effective August 24, 2026
Keel's one-time equity award totals $10 million: $5 million in time-based RSUs and $5 million in PSUs at target
CFO Eric Hammes received a special PSU award valued at $1.5 million, granted August 18, 2026
Envista reported second-quarter 2026 sales of $730.5 million, up 7.1% from a year earlier, and GAAP diluted EPS of $0.33 versus $0.16. The company raised its full-year 2026 guidance for core sales growth, adjusted EBITDA growth and adjusted diluted EPS, which now stands at $1.50 to $1.55 compared with the prior $1.35 to $1.45.
Q2 2026 GAAP net income was $53.7 million versus $26.4 million, and adjusted diluted EPS was $0.41 versus $0.26
Adjusted EBITDA was $107.7 million, up from $84.3 million, with a 14.7% adjusted EBITDA margin on sales
Full-year 2026 adjusted diluted EPS guidance was raised to $1.50 to $1.55 from $1.35 to $1.45; core sales growth guidance rose to 3.5% to 4.5% from 2% to 4%
Envista Holdings said Chief Accounting Officer Faez Kaabi will retire effective August 6, 2026, and that he is not leaving over any disagreement on accounting or disclosure matters. The company appointed Coree Thomas, its current Vice President, Global Controller, to succeed him in that role on the same date.
Faez Kaabi notified the company on May 28, 2026 of his intention to resign as Chief Accounting Officer, effective August 6, 2026.
Kaabi will continue in his current role until then to assist with the transition.
Coree Thomas, age 48, was appointed on June 2, 2026 as Vice President and Chief Accounting Officer, effective August 6, 2026.
Thomas has been Envista's Vice President, Global Controller since joining in February 2023.
Envista reported first-quarter 2026 sales of $706 million, up 14.4% from a year earlier, with GAAP diluted EPS of $0.23 versus $0.10. The company reaffirmed its full-year 2026 guidance and authorized an incremental $300 million share repurchase program running through December 31, 2029, which the filing says is in addition to the $41 million remaining under its existing program.
Sales of $706 million; core sales growth of 9.5%, with Specialty Products & Technologies at 8.4% and Equipment & Consumables at 11.5%
GAAP diluted EPS of $0.23 vs. $0.10; adjusted diluted EPS of $0.36 vs. $0.24 (+50%)
Free cash flow was negative $16 million (negative $15.7 million) vs. negative $5 million in Q1 2025
Board authorized $300 million buyback on May 5, 2026; 2026 guidance maintained, including adjusted diluted EPS of $1.35 to $1.45
Envista reported fourth-quarter 2025 sales of $751 million, up from $652.9 million a year earlier, and GAAP net income of $33 million, compared with $1 million in the prior-year quarter. The company also issued full-year 2026 guidance calling for core sales growth of 2% to 4% and adjusted diluted EPS of $1.35 to $1.45, giving shareholders a first look at its outlook for the year.
Q4 2025 sales were $751 million, with core sales growth of 10.8%.
Q4 2025 GAAP diluted EPS was $0.20 versus $0.01 a year earlier; adjusted diluted EPS was $0.38 versus $0.24.
2026 guidance: core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, adjusted diluted EPS of $1.35 to $1.45.
Full-year 2025 share repurchases totaled about $166 million, with about $84 million of repurchase capacity remaining at year-end.
Envista reported third-quarter 2025 sales of $670 million, up 11.5% from a year earlier, and adjusted diluted EPS of $0.32 versus $0.12. The company posted a GAAP net loss of $30 million, driven by a tax charge tied to restructuring certain intercompany loans, and raised the low end of its full-year adjusted EPS guidance to $1.10 to $1.15.
Q3 2025 sales were $670 million, up from $601 million, with core sales growth of 9.4%.
GAAP net loss of $30 million, or $0.18 per diluted share, reflected a tax charge from restructuring certain intercompany loans; adjusted EPS was $0.32 versus $0.12.
Full-year 2025 adjusted diluted EPS guidance is $1.10 to $1.15, up from $1.05 to $1.15; core sales growth guidance is about 4%, up from 3% to 4%.
Repurchased 2.1 million shares for about $41 million in the quarter, leaving $108 million under the repurchase program.
Envista Holdings director Barbara B. Hulit submitted her resignation from the board on September 15, 2025, effective September 26, 2025. The company said she is leaving to pursue another opportunity and that the decision did not stem from any disagreement with the company on its operations, policies or practices.
Barbara B. Hulit resigned from the Envista board, effective September 26, 2025
Resignation submitted September 15, 2025; filing dated September 17, 2025
Company states she is leaving to pursue another opportunity, not due to a disagreement
Envista reported second-quarter 2025 sales of $682 million, up from $633 million a year earlier, and GAAP net income of $26 million, compared with a net loss of $1,152 million in the prior-year quarter that included a goodwill and intangible asset impairment. The company raised its full-year 2025 guidance, lifting core sales growth to 3% to 4% and adjusted diluted EPS to $1.05 to $1.15 from prior ranges of 1% to 3% and $0.95 to $1.05.
Q2 2025 sales were $682.1 million; core sales growth was 5.6%, and adjusted diluted EPS was $0.26, up from $0.11.
GAAP diluted EPS was $0.16 in Q2 2025, compared with a loss of $6.69 in Q2 2024.
Full-year 2025 adjusted diluted EPS guidance is $1.05 to $1.15, up from $0.95 to $1.05; core sales growth guidance is 3% to 4%, up from 1% to 3%.
During Q2 2025 the company repurchased 4.8 million shares for about $82 million and had $150 million remaining under its repurchase program.
Envista Holdings elected J. Andrew Pierce, Group President of Stryker's MedSurg & Neurotechnology group, to its board effective July 14, 2025, increasing the board from eight to nine members. He also joined the Audit Committee, which the board determined he is independent to serve on.
Pierce elected to the board effective July 14, 2025, with a term running until the 2026 Annual Meeting of Stockholders
Board increased from eight members to nine
Pierce joined the Audit Committee; the committee now includes Ms. Tsingos (Chair), Mr. Huennekens and Mr. Pierce
He will receive a pro-rated standard annual retainer for the rest of fiscal 2025, plus director equity awards and expense reimbursement
Envista reported first-quarter 2025 results for the quarter ended March 28, 2025, with sales of $617 million, down from $623.6 million a year earlier, and net income of $18 million, down from $23.6 million. The company said it is maintaining its full-year 2025 guidance, including core sales growth of 1% to 3% and adjusted EPS of $0.95 to $1.05.
Sales were $616.9 million versus $623.6 million in Q1 2024; core sales rose 0.2%.
Diluted EPS was $0.10 versus $0.14; adjusted diluted EPS was $0.24 versus $0.26.
Operating cash flow was $0.3 million and free cash flow was negative $5.1 million, compared with $40.3 million and $29.3 million a year earlier.
Full-year 2025 guidance was maintained, and $231 million remained under the repurchase program at quarter end after $19 million of Q1 buybacks.
Envista reported fourth-quarter 2024 sales of $652.9 million, up 1.1% from a year earlier, and GAAP net income of $1.2 million, compared with a loss of $217.4 million in the same quarter of 2023. Adjusted diluted EPS fell to $0.24 from $0.29, and adjusted EBITDA declined to $91.0 million, so headline profit measures moved in different directions. The company also issued full-year 2025 guidance and reported a full-year 2024 net loss of $1,118.6 million, driven by a $1,153.8 million goodwill and intangible asset impairment.
Q4 2024 sales were $652.9 million, with core sales up 2.0%; GAAP diluted EPS was $0.01 versus a loss of $1.27 a year earlier
Q4 2024 adjusted EBITDA was $91.0 million, down from $100.5 million, with a margin of 13.9% versus 15.6%
Full-year 2024 net loss was $1,118.6 million, including a $1,153.8 million goodwill and intangible asset impairment
2025 guidance calls for core sales growth of 1% to 3%, adjusted EBITDA margin of about 14%, and adjusted EPS of $0.95 to $1.05, compared with full-year 2024 adjusted EPS of $0.73
Envista reported third-quarter 2024 sales of $601.0 million, down from $631.3 million a year earlier, with core sales down 5.3%. GAAP net income fell to $8.2 million, or $0.05 per diluted share, from $21.5 million, and adjusted diluted EPS fell to $0.12 from $0.43. The company kept its full-year 2024 outlook of core sales growth of -1% to -4% and adjusted EBITDA margins of 10% to 12%, but nine-month GAAP results include a $1.15 billion goodwill and intangible asset impairment.
Q3 2024 sales $601.0 million vs. $631.3 million in Q3 2023; core sales declined 5.3%.
Q3 GAAP net income $8.2 million ($0.05 per diluted share) vs. $21.5 million ($0.12) a year earlier.
Adjusted EBITDA $54.9 million vs. $123.5 million; adjusted diluted EPS $0.12 vs. $0.43.
2024 guidance unchanged: core sales growth of -1% to -4% and adjusted EBITDA margins of 10% to 12%; company expects a return to growth in Q4.
Envista reported second-quarter 2024 sales of $633.1 million, down from $662.4 million a year earlier, and a net loss of $1,151.6 million, or $6.69 per share, driven by a $1,153.8 million non-cash goodwill and intangible asset impairment. Adjusted EPS fell to $0.11 from $0.43, and the company guided to a 1% to 4% core sales decline for full-year 2024, with a further decline expected in the third quarter.
Q2 sales were $633.1 million, down from $662.4 million; core sales declined 3.2%.
Net loss was $1,151.6 million, or $6.69 per share, including a $1,153.8 million non-cash impairment charge.
Adjusted EPS was $0.11 versus $0.43; adjusted EBITDA was $63.0 million versus $126.2 million.
For 2024, the company expects core sales to decline 1% to 4% and adjusted EBITDA margins of 10% to 12%.
Envista Holdings appointed Eric Hammes, formerly Vice President of Corporate Financial Planning & Analysis at Rockwell Automation, as Senior Vice President and Chief Financial Officer, effective August 8, 2024. He succeeds Stephen Keller, who has served as Interim Principal Financial Officer since September 2023 and will return to leading investor relations. The filing also announces two other leadership appointments, a change in top finance leadership that shareholders may track.
Eric Hammes becomes CFO effective August 8, 2024; he is 49 and previously held senior finance roles at 3M
Hammes' pay includes a $575,000 base salary, a 75% target incentive, and a one-time lump sum bonus of $1,020,000 subject to a 12-month clawback
Stephen Keller, Interim Principal Financial Officer since September 2023, will return to his previous role leading investor relations
Stefan Nilsson joins as President, Nobel Biocare, effective July 15, 2024; Veronica Acurio joins as President, Orthodontics, effective August 2, 2024
Envista Holdings disclosed that Eric Conley, SVP and President of Orthodontics, will step down effective June 3, 2024 to pursue another opportunity. The company said the decision was not the result of any disagreement with the company.
Eric Conley notified Envista on May 27, 2024 that he will step down as SVP and President, Orthodontics.
His departure takes effect June 3, 2024.
Conley is leaving to pursue another opportunity; the filing states no disagreement with the company.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Envista filing is on SEC EDGAR ↗. 8-K briefs of other companies →